Published on
April 29, 2025
- 21:28 GMT
InVitria Launches OptiLeukin 2: A Chemically Defined Recombinant IL-2 for Cell Therapy
Animal- and bacteria-free recombinant IL-2 enables safer, scalable immune cell expansion for CAR-T, NK, and iPSC-derived cell therapy workflows. JUNCTION CITY, KS, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- InVitria Launches OptiLeukin™ 2: A …
Distribution channels:
Chemical Industry, Companies
...
